Good-Heart6425
GLP-1 Enthusiast
Four obesity stereotypes [some are GLP resistant]
- Thread starter Good-Heart6425
- Start date
- Status
Mr.Tired
GLP-1 Apprentice
"The cheek-swab genetic test groups people into four basic obesity phenotypes (meaning observable traits): Hungry Gut, Hungry Brain, Emotional Hunger, and Slow Burn. (A person might belong to more than one of these groups.)"
Hungry Brain - Individuals who feel persistently hungry despite eating enough calories.
Hungry Gut - Those who feel full but experience quick returns of hunger due to faster gastric emptying.
Emotional Hunger - People who eat in response to emotional triggers rather than physical hunger.
Slow Burn - Individuals with a lower metabolic rate, making weight maintenance challenging.
Tag yourself, I'm Emotional Hunger all the way to the moon and back.
Hungry Brain - Individuals who feel persistently hungry despite eating enough calories.
Hungry Gut - Those who feel full but experience quick returns of hunger due to faster gastric emptying.
Emotional Hunger - People who eat in response to emotional triggers rather than physical hunger.
Slow Burn - Individuals with a lower metabolic rate, making weight maintenance challenging.
Tag yourself, I'm Emotional Hunger all the way to the moon and back.
Good-Heart6425
GLP-1 Enthusiast
AI Overview GLP-1 receptor agonists (GLP-1RAs) show potential for treating diabetic peripheral neuropathy (DPN) by
improving nerve structure, function, and alleviating pain, potentially through neuroprotective and anti-inflammatory mechanisms. Studies suggest they may improve nerve size and axonal function, with some evidence showing reversal of nerve damage.
Key Aspects of GLP-1 for DPN:
Positive Effects: Research indicates that GLP-1RAs can lead to improvements in nerve conduction studies, clinical neuropathy scores, and nerve fiber structure, with one study showing 93% of patients had improved nerve size at 3 months.
Mechanisms: These medications may work independently of weight loss, possibly by enhancing
Na+/K+cap N a raised to the positive power / cap K raised to the positive power
-ATPase pump function, reducing inflammation, and protecting nerve cells.
Pain Reduction: Preliminary evidence suggests a significant reduction in peripheral neuropathy pain, according to PubMed.
Current Status: While findings are promising, they are based on smaller studies and preclinical models. Larger, long-term trials are necessary to confirm efficacy and establish optimal usage.
Potential Risks: Some, though not all, studies have raised questions about a potential association between GLP-1RA use and an increased risk of a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION).
Combination Treatment: Research indicates that combinations, such as the experimental drug CagriSema, are being investigated for stronger effects, notes diaTribe.
It is essential for patients to consult healthcare providers regarding the management of DPN and the use of these medications.
Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy - PubMed
Mar 15, 2024 — According to a study, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can improve nerve structure in patients with diabetic ...
National Institutes of Health (NIH) | (.gov)
Impact of glucagon-like peptide-1 receptor agonists on axonal ...
Dec 23, 2024 — GLP-1RA therapy improves clinical and neurophysiological outcomes in DPN. Treatment with GLP-1RA may reverse axonal dysfunction by...
View attachment 15000
American Physiological Society Journal
View attachment 15002
Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 ...
Apr 26, 2025 — Furthermore, GLP-1RAs may facilitate the regeneration of peripheral nerves, providing a dual therapeutic effect of pain relief and...
National Institutes of Health (NIH) | (.gov)
Glucagon-like peptide-1 receptor agonists in neuropathic pain
Jul 1, 2025 — Despite promising preclinical findings, clinical evidence supporting the use of GLP-1RAs for neuropathic pain remains limited [5,6...
View attachment 15001
The Korean Journal of Pain
View attachment 15003
Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy
Jan 18, 2024 — Glucagon-like peptide-1 receptor (GLP-1R) agonists may have neuroprotective effects in diabetic peripheral neuropathy (DPN). DPN i...
Frontiers
GLP-1 agonists: a game changer in pain treatment and addiction
Jul 28, 2025 — These medications act on various parts of the body, including the brain and nervous system. They may reduce inflammation, protect ...
View attachment 15004
National Institutes of Health (NIH) | (.gov)
Trial Testing New GLP-1 Drug To Reduce Pain of Peripheral ...
Nov 17, 2025 — At the moment, there is no cure or disease-modifying treatment for painful diabetes-related peripheral neuropathy, but people can ...
diaTribe
GLP-1 RA Weight Loss Drugs May Carry Untold Ocular Burden
Jul 3, 2025 — 11. Similarly, a systematic review and meta-analysis of 60 randomized controlled trials with 60,077 patients showed that the incid...
View attachment 15006
improving nerve structure, function, and alleviating pain, potentially through neuroprotective and anti-inflammatory mechanisms. Studies suggest they may improve nerve size and axonal function, with some evidence showing reversal of nerve damage.
Key Aspects of GLP-1 for DPN:
Positive Effects: Research indicates that GLP-1RAs can lead to improvements in nerve conduction studies, clinical neuropathy scores, and nerve fiber structure, with one study showing 93% of patients had improved nerve size at 3 months.
Mechanisms: These medications may work independently of weight loss, possibly by enhancing
Na+/K+cap N a raised to the positive power / cap K raised to the positive power
-ATPase pump function, reducing inflammation, and protecting nerve cells.
Pain Reduction: Preliminary evidence suggests a significant reduction in peripheral neuropathy pain, according to PubMed.
Current Status: While findings are promising, they are based on smaller studies and preclinical models. Larger, long-term trials are necessary to confirm efficacy and establish optimal usage.
Potential Risks: Some, though not all, studies have raised questions about a potential association between GLP-1RA use and an increased risk of a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION).
Combination Treatment: Research indicates that combinations, such as the experimental drug CagriSema, are being investigated for stronger effects, notes diaTribe.
It is essential for patients to consult healthcare providers regarding the management of DPN and the use of these medications.
Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathy - PubMed
Mar 15, 2024 — According to a study, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can improve nerve structure in patients with diabetic ...
National Institutes of Health (NIH) | (.gov)
Impact of glucagon-like peptide-1 receptor agonists on axonal ...
Dec 23, 2024 — GLP-1RA therapy improves clinical and neurophysiological outcomes in DPN. Treatment with GLP-1RA may reverse axonal dysfunction by...
View attachment 15000
American Physiological Society Journal
View attachment 15002
Therapeutic Effects of GLP-1 Receptor Agonists and DPP-4 ...
Apr 26, 2025 — Furthermore, GLP-1RAs may facilitate the regeneration of peripheral nerves, providing a dual therapeutic effect of pain relief and...
National Institutes of Health (NIH) | (.gov)
Glucagon-like peptide-1 receptor agonists in neuropathic pain
Jul 1, 2025 — Despite promising preclinical findings, clinical evidence supporting the use of GLP-1RAs for neuropathic pain remains limited [5,6...
View attachment 15001
The Korean Journal of Pain
View attachment 15003
Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy
Jan 18, 2024 — Glucagon-like peptide-1 receptor (GLP-1R) agonists may have neuroprotective effects in diabetic peripheral neuropathy (DPN). DPN i...
Frontiers
GLP-1 agonists: a game changer in pain treatment and addiction
Jul 28, 2025 — These medications act on various parts of the body, including the brain and nervous system. They may reduce inflammation, protect ...
View attachment 15004
National Institutes of Health (NIH) | (.gov)
Trial Testing New GLP-1 Drug To Reduce Pain of Peripheral ...
Nov 17, 2025 — At the moment, there is no cure or disease-modifying treatment for painful diabetes-related peripheral neuropathy, but people can ...
diaTribe
GLP-1 RA Weight Loss Drugs May Carry Untold Ocular Burden
Jul 3, 2025 — 11. Similarly, a systematic review and meta-analysis of 60 randomized controlled trials with 60,077 patients showed that the incid...
View attachment 15006
Mr.Tired
GLP-1 Apprentice
I've been taking 2mg of reta for a little over a month and it is definitely working.toologic said:
Good-Heart6425
GLP-1 Enthusiast
Humbly apologize for copy/paste above.
randompersonrandom
GLP-1 Specialist
Good-Heart6425 said:
It's not just you. It's becoming common, and irritating. I have snarled more than once this week at work "Stop puking AI slop at me. If the solution was something the lying machine had enough understanding of nuance and accuracy to do well, I wouldn't have needed to bother asking you in the first place." It's going to get common enough in time to annoy EVERYBODY, and then we'll all stop doing it, but for now, it's a thing.
Calm Logic
GLP-1 Specialist
Regarding the appreciated info on GLPs for peripheral neuropathy, the higher the dose the better it seems, like 8 mg for reta and 10 mg for tirz. Above that, may be diminishing returns (on average) for weight loss, metabolic bloodwork, and other benefits.
As alluded to, cagri may also help, including in different ways for nerve issues, since amylin receptors are throughout the nervous system. ARA-290 is promising for nerve repair based on human studies but requires cycling to prevent unknown long-term effects.
You can always put in quotes:
Code:
which will make any long text just a few lines.
As alluded to, cagri may also help, including in different ways for nerve issues, since amylin receptors are throughout the nervous system. ARA-290 is promising for nerve repair based on human studies but requires cycling to prevent unknown long-term effects.
Good-Heart6425 said:
You can always put in quotes:
Code:
Chat GPT said:
which will make any long text just a few lines.
MsGizmo
GLP-1 Enthusiast
I think I would be "slow burn" because I don't really eat a lot. I also have a problem with sugar .. even when I don't have a large portion sugar still causes issues.Mr.Tired said:
- Status
